GlassScriptPhysician profile
Naiff Ali
NPI 1992151401
$12,448.30
in general payments reported to CMS, 2019-2025
48 companies · $2,856 in 2025
The $2,856 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.50 · 2020: $248 · 2021: $2,014 · 2022: $2,234 · 2023: $2,860 · 2024: $2,224 · 2025: $2,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,939.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,051.19 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,675.13 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,443.72 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,347.34 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $996.36 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $483.73 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.07 | 2020-2025 | Jardiance, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $365.64 | 2020-2025 | Xarelto, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $343.35 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $293.68 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $258.43 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $222.10 | 2022-2025 | Eliquis, Camzyos |
| Amgen INC. | $216.07 | 2020-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $209.74 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $197.28 | 2023-2025 | Rexulti |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $176.75 | 2022-2025 | Symbravo, Auvelity |
| Amarin Pharma, INC. | $166.55 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $139.14 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $122.89 | 2021 | |
| Amag Pharmaceuticals, INC. | $107.84 | 2021 | |
| Lundbeck LLC | $101.04 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $98.39 | 2023-2025 | Veozah |
| Abbott Laboratories | $91.60 | 2022-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $83.57 | 2019-2025 | Verquvo |
| Exact Sciences Corporation | $81.32 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $76.99 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $76.85 | 2021-2023 | |
| Alkermes, INC. | $69.92 | 2023-2025 | Aristada, Vivitrol, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $64.86 | 2023 | Austedo Xr |
| Amneal Pharmaceuticals LLC | $61.97 | 2022-2023 | Unithroid |
| Aimmune Therapeutics, INC. | $54.77 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $46.22 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $39.89 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $34.02 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $30.78 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $27.98 | 2020-2021 | |
| Allergan, INC. | $27.10 | 2021 | |
| Medtronic, INC. | $24.00 | 2023 | Interstim |
| Hologic Sales and Service, LLC | $21.26 | 2025 | Thinprep 2000 Processor, Aptima |
| Corcept Therapeutics | $20.57 | 2025 | Korlym |
| Verona Pharma, INC. | $17.79 | 2025 | Ohtuvayre |
| Horizon Therapeutics Plc | $17.56 | 2023 | Krystexxa |
| Inari Medical, INC. | $16.85 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alexion Pharmaceuticals, INC. | $16.70 | 2024 | Ultomiris |
| Qiagen, LLC | $15.60 | 2020 | |
| Currax Pharmaceuticals LLC | $14.99 | 2025 | Contrave |
| Dermira, INC. | $12.60 | 2020 | |
| Echosens North America, INC. | $9.11 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naiff Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.